Kowa Pharmaceuticals America, Inc. Announces Agreement with CymaBay Therapeutics to License Gout Compound
pharamaceutical | January 03, 2017
Kowa Pharmaceuticals America, Inc., a U.S. subsidiary of Kowa Company Ltd., a privately held, multinational company based in Japan, today announced that it has entered into a licensing agreement with San Francisco-based CymaBay Therapeutics (Nasdaq:CBAY), a clinical-stage biopharmaceutical company, for exclusive US rights to arhalofenate, a compound in late stage clinical development for the treatment of gout.